N-linoleyltyrosine resisted the growth of non-small cell lung cancer cells via the regulation of CB₁ and CB₂ involvement of PI3K and ERK pathways.

ABSTRACT: Background: N-linoleyltyrosine (NITyr), one of the anandamide analogs, exerts activity via the endocannabinoid receptors (CB₁ and CB₂), which showed anti-tumor effects in various tumors. Therefore, we speculated that NITyr might show anti-non-small cell lung cancer (NSCLC) effects via the CB₁ or CB₂ receptor. The purpose of the investigation was to reveal the anti-tumor ability of NITyr on A549 cells and its mechanisms. Methods: The viability of A549 cells was measured by MTT assay, and the cell cycle and apoptosis were both examined by flow cytometry; in addition, cell migration was tested by wound healing assay. Apoptosis-related markers were measured by immunofluorescence. The downstream signaling pathways (PI3K, ERK, and JNK) of

SUBMITTER: Hu Y 

PROVIDER: S-EPMC10285528 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature